drugset

drugset / Trial / NCT01174823

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

NCT01174823 ↗

Phase 2 Completed 245 enrolled Bausch & Lomb Incorporated

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.

Timeline

Start: 2010-06
Primary completion: 2010-10
Completion: 2010-12

Publications

Carr WW, Nayak AS, Ratner PH, Gow JA, McNamara TR, Williams JI; Bepotastine Besilate Ophthalmic Solution 1.5% (Bepreve) Study Group. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. Allergy Asthma Proc. 2013 May-Jun;34(3):247-54. doi: 10.2500/aap.2013.34.3671.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bepotastine	Small molecule	1.5 %	Other

Indications